Press release from Thermo Fisher (and the once great Oxoid brand):
Thermo Fisher Scientific recently announced it has entered into an agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm with deep expertise in healthcare, focused on a select set of subsectors, including pharmaceutical services and technology, medtech and related services, life science tools, and diagnostics.
Read about Oxoid's hisotry here: History and development of microbiological culture media
For 100 years, we have been dedicated to serving microbiologists. From antibiotic resistance monitoring, to safeguarding the integrity of the global food supply chain, our tools have aided microbiology leaders in their essential work since 1924, and we expect that to continue as part of Astorg. We are confident that with Astorg as owners, the microbiology business will benefit from its industry expertise in healthcare creating an environment where it can thrive and further unlock its full potential.
This decision follows a thoughtful evaluation as part of Thermo Fisher’s ongoing business strategy to actively manage and strengthen our portfolio. The microbiology business has built strong capabilities, talented teams and a solid operational foundation. We believe that under Astorg’s ownership, with focused investment and strategic attention, it will be well positioned to further accelerate growth and continue delivering high value to customers.
We expect the transaction will be completed in the second half of 2026, subject to customary closing conditions and applicable regulatory approvals. Until the transaction is complete, Thermo Fisher will continue to operate the microbiology business.
No comments:
Post a Comment
Pharmaceutical Microbiology Resources